Scarica l'app Stockscreener
139.90
0.60%
-0.84
Precedente Chiudi:
$140.74
Aprire:
$140.74
Volume 24 ore:
837.45K
Relative Volume:
0.45
Capitalizzazione di mercato:
$12.19B
Reddito:
-
Utile/perdita netta:
$-386.19M
Rapporto P/E:
-26.62
EPS:
-5.2547
Flusso di cassa netto:
$-206.27M
1 W Prestazione:
-3.28%
1M Prestazione:
+42.71%
6M Prestazione:
+22.29%
1 anno Prestazione:
+1,586%
Intervallo 1D:
$137.72
$141.00
Intervallo di 1 settimana:
$136.85
$147.98
Portata 52W:
$8.05
$148.83
Abivax Adr Stock (ABVX) Company Profile
Compare ABVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
139.90 | 12.19B | 0 | -386.19M | -206.27M | -5.2547 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Iniziato | Jefferies | Buy |
| 2026-02-24 | Iniziato | Wedbush | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-06 | Iniziato | Wolfe Research | Outperform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-07-23 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-03-20 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-12-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-29 | Iniziato | Laidlaw | Buy |
| 2024-05-20 | Iniziato | BTIG Research | Buy |
| 2024-04-29 | Iniziato | Guggenheim | Buy |
| 2024-04-29 | Iniziato | Piper Sandler | Overweight |
| 2023-11-14 | Iniziato | Leerink Partners | Outperform |
| 2023-11-14 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Abivax Adr Borsa (ABVX) Ultime notizie
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross? - Yahoo Finance
3 Soaring Stocks That May Have More Upside Ahead - The Motley Fool
2X10 Forecast — Price Target — Prediction for 2027 - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Abivax’s Hot Rally Is Suddenly Cooling Off - TipRanks
Weekly Recap: Upsized $920M ADS offering and Obefazimod UC results - TradingView
Pictet Asset Management Holding SA Reduces Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax SA Raises $760 Million in Major U.S. ADS Offering - TipRanks
Abivax Slides As Massive Stock Offering Spooks Traders - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why is Abivax stock climbing today? - Investing.com UK
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June - Sahm
Abivax stock surges on Phase 3 ulcerative colitis data By Investing.com - Investing.com Nigeria
Abivax Posts Positive Phase 3 Maintenance Data for Obefazimod in Refractory Ulcerative Colitis - TipRanks
Abivax Stock Slides as Phase 3 Update Disappoints - TipRanks
Abivax SA sponsored ADR (ABVX) loses 41.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Abivax SA Sponsored ADR Actuals & Estimates (NASDAQ:ABVX) - TradingView
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai - Bitget
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Icon (ICLR) and Liquidia Technologies (LQDA) - The Globe and Mail
ABVX News | ABIVAX SA-ADR (NASDAQ:ABVX) - ChartMill
Abivax Soars As New Crohn’s Trial Ignites Hopes - TipRanks
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Guggenheim - The Globe and Mail
Barclays Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Why Abivax SA Sponsored ADR Stock Is Sinking - TipRanks
Why Abivax Shares Are Sinking Despite Trial Success - TipRanks
ABIVAX SA-ADR (ABVX) Stock Chart - ChartMill
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Bausch Health Companies (BHC) and Healthequity (HQY) - The Globe and Mail
Abivax SA Sponsored ADR (ABVX) Loses 41.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Why Abivax SA Sponsored ADR Shares Are Sinking - TipRanks
Why This Biotech Plummeted Despite Its 'Best-Case' Study - Investor's Business Daily
Truist cuts Abivax stock price target on malignancy concerns By Investing.com - Investing.com Australia
Abivax shares sink as rare malignancy events cloud strong colitis trial data - Investing.com UK
Why Abivax SA Sponsored ADR Shares Are Sliding - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
What makes Abivax SA sponsored ADR (ABVX) a strong momentum stock: Buy now? - MSN
ABVX Technical Analysis | Trend, Signals & Chart Patterns | ABIVAX SA-ADR (NASDAQ:ABVX) - ChartMill
ABVX Q4 2025 Earnings: Wider-Than-Expected Loss Highlights Clinical-Stage Biotech ChallengesWeak Earnings Momentum - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and TG Therapeutics (TGTX) - The Globe and Mail
What Makes Abivax SA Sponsored ADR (ABVX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Barclays - The Globe and Mail
ABVXAbivax ADR Stock Price and Quote - Finviz
Abivax Adr Azioni (ABVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):